Comprehensive Guide to Addiction Medications and T
This detailed chart outlines key addiction medications, their indications, neurotransmitter targets, side effects, dosing, and special considerations for age, pregnancy, and breastfeeding in the treatment of opioid and alcohol dependence.
Mason Bennett
Contributor
4.4
33
2 months ago
Preview (2 of 5)
Sign in to access the full document!
Addiction Medications Table
Week B
CH O W Bl. M N H M V n t M T V
“HIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 5 MEDICATION TABLE DROPBOX BY SUNDAY AT 11 59 P.M. MT.
Drug Name Indication
Neurotransmitterfs)
Affected
Target Symptoms
Half-life (Tl'2),
Metabolism (CYP 450
enzyme)
Notable Side Effects
(link to NT or affected
brain circuit)
Initial Dosing
Considerations
Specific lifespan
considerations
(age, pregnancy,
breastfeeding)
Buprenorphine
(Subutex)
Indication:
Maintenance
treatment of opioid
dependence
Maintenance
treatment of opioid
dependence in
patients who have
achieved and
sustained prolonged
clinical stability on
low-to moderate
doses of a trans
mucosal
buprenorphine
containing product
Moderate to severe
opioid use disorder in
patients who have
initiated treatment
with a transmucosal
24-42
hours
CYP450:
CYP3A4
24-42
hours
CYP450:
CYP3A4
Half-life: 24-42 hours
CYP450: CYP3A4
Headache,
constipation, nausea
Oral hypoesthesia,
glosscdynia
Orthostatic
hypotension
Respiratory distress
Hepatotoxicity
Binds to mu opioid
receptors
Initial dosing:
Sublingual 8-32
mg day
Controlled studies
have not been
conducted in
pregnant women.
Buprenorphine
may be preferable
to methadone in
pregnant women.
Neonatal opioid
withdrawal
syndrome has been
reported following
use of
Buprenorphine
during pregnancy
Some drag is
buprenorphine
containing product,
followed by dose
adjustment for a
minimum of 7 days
Neurotransmitter
affected: Mu opioid
receptor partial
agonist Antagonist at
the kappa opioid
receptor
Target symptoms:
Opioid dependence
found in mother's
breast milk.
Recommended
either to
discontinued drug
or formula feed.
Use with caution
in elderly. Some
patients may
tolerate lower
doses better.
Buprenorphine Naloxone
(Suboxone, Zubsolv,
Bunavail)
Indication:
Treatment, and
maintenance of
opioid dependence.
Induction of
treatment for opioid
dependence
Maintenance
treatment of opioid
dependence in
patients who have
achieved and
sustained prolonged
clinical stability on
low-to moderate
Suboxone: 24-42 hours
Naloxone: 2-12 hours
CYP450: CYP3A4
Headache,
constipation, nausea,
oral hypcesthesia,
glosscdynia,
orthostatic
hypotension, sedation
Binding at mu opioid
receptors
Initial dosing:
Bunavail: Day 1:
induction dose:
Initial: Buccal:
Buprenorphine 2.1
mg naloxone 0.3
mg ; may repeat
dose after 2 hours,
based on control of
acute withdrawal
symptoms;
maximum total
dose:
buprenorphine 4.2
mg naloxone 0.7
mg. Day 2:
Week B
CH O W Bl. M N H M V n t M T V
“HIS ASSIGNMENT SHOULD BE SUBMITTED TO THE WEEK 5 MEDICATION TABLE DROPBOX BY SUNDAY AT 11 59 P.M. MT.
Drug Name Indication
Neurotransmitterfs)
Affected
Target Symptoms
Half-life (Tl'2),
Metabolism (CYP 450
enzyme)
Notable Side Effects
(link to NT or affected
brain circuit)
Initial Dosing
Considerations
Specific lifespan
considerations
(age, pregnancy,
breastfeeding)
Buprenorphine
(Subutex)
Indication:
Maintenance
treatment of opioid
dependence
Maintenance
treatment of opioid
dependence in
patients who have
achieved and
sustained prolonged
clinical stability on
low-to moderate
doses of a trans
mucosal
buprenorphine
containing product
Moderate to severe
opioid use disorder in
patients who have
initiated treatment
with a transmucosal
24-42
hours
CYP450:
CYP3A4
24-42
hours
CYP450:
CYP3A4
Half-life: 24-42 hours
CYP450: CYP3A4
Headache,
constipation, nausea
Oral hypoesthesia,
glosscdynia
Orthostatic
hypotension
Respiratory distress
Hepatotoxicity
Binds to mu opioid
receptors
Initial dosing:
Sublingual 8-32
mg day
Controlled studies
have not been
conducted in
pregnant women.
Buprenorphine
may be preferable
to methadone in
pregnant women.
Neonatal opioid
withdrawal
syndrome has been
reported following
use of
Buprenorphine
during pregnancy
Some drag is
buprenorphine
containing product,
followed by dose
adjustment for a
minimum of 7 days
Neurotransmitter
affected: Mu opioid
receptor partial
agonist Antagonist at
the kappa opioid
receptor
Target symptoms:
Opioid dependence
found in mother's
breast milk.
Recommended
either to
discontinued drug
or formula feed.
Use with caution
in elderly. Some
patients may
tolerate lower
doses better.
Buprenorphine Naloxone
(Suboxone, Zubsolv,
Bunavail)
Indication:
Treatment, and
maintenance of
opioid dependence.
Induction of
treatment for opioid
dependence
Maintenance
treatment of opioid
dependence in
patients who have
achieved and
sustained prolonged
clinical stability on
low-to moderate
Suboxone: 24-42 hours
Naloxone: 2-12 hours
CYP450: CYP3A4
Headache,
constipation, nausea,
oral hypcesthesia,
glosscdynia,
orthostatic
hypotension, sedation
Binding at mu opioid
receptors
Initial dosing:
Bunavail: Day 1:
induction dose:
Initial: Buccal:
Buprenorphine 2.1
mg naloxone 0.3
mg ; may repeat
dose after 2 hours,
based on control of
acute withdrawal
symptoms;
maximum total
dose:
buprenorphine 4.2
mg naloxone 0.7
mg. Day 2:
doses of a trans
mucosal
Neurotransmitters:
Antagonist at the
kappa opioid receptor
Mu opioid receptor
partial agonist
Target symptoms:
Opioid dependence
induction dose: Up
to buprenorphine
8.4 mg naloxone
1.4 mg as a single
dose Suboxone:
Day 1: induction
dose: Initial:
Sublingual:
Buprenorphine 2
mg naloxone 0.5
mg or
buprenorphine 4
mg naloxone 1
mg; may titrate
dose, based on
control of acute
withdrawal
symptoms, in
buprenorphine 2
mg naloxone 0.5
mg or
buprenorphine 4
mg naloxone 1 mg
increments
approximately
every 2 hours up to
a total dose of
buprenorphine 8
mg naloxone 2
mg. Day 2:
induction dose:
Sublingual: Up to
buprenorphine 16
mg naloxone 4 mg
as a single dose.
Zubsolv: Day 1:
induction dose:
Sublingual: Stan
with an initial dose
of buprenorphine
1.4 mg naloxone
C.36 mg; based on
control of acute
withdrawal
symptoms, may
administer
additional doses in
increments of 1 to
2 buprenorphine
1.4 mg naloxone
C.36 mg tablets
every 1.5 to 2
hours to a total day
1 dose up to
buprenorphine 5.7
mg naloxone 1.4
mg. Some patients
(eg, those with
recent exposure to
buprenorphine)
may tolerate up to
buprenorphine 4.2
mg naloxone 1.08
mg as a single,
mucosal
Neurotransmitters:
Antagonist at the
kappa opioid receptor
Mu opioid receptor
partial agonist
Target symptoms:
Opioid dependence
induction dose: Up
to buprenorphine
8.4 mg naloxone
1.4 mg as a single
dose Suboxone:
Day 1: induction
dose: Initial:
Sublingual:
Buprenorphine 2
mg naloxone 0.5
mg or
buprenorphine 4
mg naloxone 1
mg; may titrate
dose, based on
control of acute
withdrawal
symptoms, in
buprenorphine 2
mg naloxone 0.5
mg or
buprenorphine 4
mg naloxone 1 mg
increments
approximately
every 2 hours up to
a total dose of
buprenorphine 8
mg naloxone 2
mg. Day 2:
induction dose:
Sublingual: Up to
buprenorphine 16
mg naloxone 4 mg
as a single dose.
Zubsolv: Day 1:
induction dose:
Sublingual: Stan
with an initial dose
of buprenorphine
1.4 mg naloxone
C.36 mg; based on
control of acute
withdrawal
symptoms, may
administer
additional doses in
increments of 1 to
2 buprenorphine
1.4 mg naloxone
C.36 mg tablets
every 1.5 to 2
hours to a total day
1 dose up to
buprenorphine 5.7
mg naloxone 1.4
mg. Some patients
(eg, those with
recent exposure to
buprenorphine)
may tolerate up to
buprenorphine 4.2
mg naloxone 1.08
mg as a single,
Preview Mode
Sign in to access the full document!
100%
Study Now!
XY-Copilot AI
Unlimited Access
Secure Payment
Instant Access
24/7 Support
Document Chat
Document Details
Subject
Pharmacology